NEW YORK (GenomeWeb News) – Compugen this week said that it has inked a deal to license to an unnamed diagnostic firm the biomarker candidate CGEN-226 for early detection of preeclampsia. Compugen used its in silico platform to identify the marker, which is a soluble splice variant of the vascular endothelial growth factor. (This brief has been corrected to state that Compugen licensed the biomarker to the unnamed partner rather than from the partner.)

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.